PA-GROVARA
19.5.2022 13:02:12 CEST | Business Wire | Press release
Grovara , the easy global wholesale experience, announces it has signed a lease agreement and become formally incorporated to do business in Dubai as part of a partnership with Dubai Global Connect (DGC) , a permanent wholesale market that facilitates business between international buyers and sellers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220519005017/en/
The partnership will integrate Grovara’s first-to-market digital global trading platform with DGC’s one-of-a-kind physical marketplace, providing unprecedented speed, reliability, and growth potential for DGC’s global wholesale buyers and sellers.
Grovara will leverage its international B2B online marketplace with DGC’s state-of-the-art showroom ecosystem for wholesale food, home furnishings, and fashion trade to supercharge CPG brands’ global distribution. Grovara’s digital platform streamlines and automates global wholesale trade, enabling buyers to find and manage suppliers and sellers while showcasing and selling goods online and managing fulfillment.
“The future of trade is digital, with a human touch. Our game-changing global marketplace will help bring Dubai Global Connect’s community of brands and buyers online,” says Grovara Co-Founder and CEO Abu Kamara. “Our technology is a turbo booster for international trade, and coupled with DGC’s state-of-the-art, bespoke physical showroom marketplace, Dubai is ready to be the launch pad.”
DGC’s facility will be one of the highlights of fast-growing Dubai South, the largest single urban master development in Dubai. Dubai South is being developed as an aviation and logistics ecosystem including a multi-modal transport infrastructure connecting air, land, and sea, and planned residential and commercial developments. DGC is located between Al Maktoum International Airport, which will be the world’s largest airport when construction is complete, and Jebel Ali Port, the Middle East’s busiest port.
With 2.5 billion people within a four-hour flight and 5 billion within an eight-hour flight, Dubai is globally recognized as an ideal place to live, work and play, while also offering transparent, business-friendly free-zone regulation across the country. The Dubai South Free Zone fosters ingenuity, offers ease of doing business, and provides comprehensive services that enable 100% foreign ownership and income and personal tax exemption.
Grovara will be the digital global wholesale option for those new businesses looking for buyers and sellers, with easy discovery, pricing, and purchasing that saves time and cost while delivering better performance via a curated marketplace. Sellers rely on Grovara’s automated export and operations document managers and achieve faster sales and brand valuations by selling to more customers.
“Our technology and in-country expertise will make it even easier for buyers and sellers from across the entire region to meet halfway in Dubai, where they’ll find all the support they need to grow,” says Grovara Sales Director Eugenia Schlitter.
DGC offers a number of physical spaces and services for brands and buyers, like showrooms, boutique offices, secure self-storage units with direct access to showrooms, and a smart service center offering a one-stop shop for a variety of business services. DGC is also planning a lavish auditorium, innovation hub, entrepreneurship center, and a year-round program of industry-specific programming.
“We are pleased to welcome Grovara to the Dubai Global Connect community here in Dubai,” says DGC’s Head of Business Development Paul Boots. “Grovara will be able to tap into DGC’s year-round physical showroom ecosystem and showcase some of the great brands available on their platform.
“Dubai is the natural gateway to the emerging markets, and the combination of Grovara and DGC will enable brands to expand their reach to a global buying audience, through Dubai. Partnerships such as these will further support DGC’s ambition to make Dubai a place of reference for the international B2B food trade, and we look forward to supporting them with the growth of their business.”
ABOUT GROVARA
Grovara enables an easy global wholesale experience as the first-to-market online marketplace supporting thousands of CPG products for export/import in more than 50 countries. With offices in Philadelphia, Mexico, and Dubai, Grovara facilitates global exporting and importing with a lightweight, tech-driven platform that provides automation and intelligence-based tools. Grovara leverages visibility, discovery, and an intuitive user experience to deliver easy transacting and management, creating a streamlined pathway to dynamic global growth potential. For more information or to join the curated ecosystem, please visit Grovara.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220519005017/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom